137 related articles for article (PubMed ID: 26783083)
41. IL-1 RN polymorphism is not associated with Barrett's esophagus and esophageal adenocarcinoma.
Moons LM; Siersema PD; Kuipers EJ; van Vliet AH; Kusters JG
Am J Gastroenterol; 2005 Dec; 100(12):2818. PubMed ID: 16393246
[No Abstract] [Full Text] [Related]
42. Association of methylenetetrahydrofolate reductase C677T-A1298C polymorphisms with risk for esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis.
Ekiz F; Ormeci N; Coban S; Karabulut HG; Aktas B; Tukun A; Tuncali T; Yüksel O; Alkış N
Dis Esophagus; 2012 Jul; 25(5):437-41. PubMed ID: 21951971
[TBL] [Abstract][Full Text] [Related]
43. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
44. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.
Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):736-9. PubMed ID: 18349297
[TBL] [Abstract][Full Text] [Related]
45. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
[TBL] [Abstract][Full Text] [Related]
46. Pleiotropic analysis of cancer risk loci on esophageal adenocarcinoma risk.
Lee E; Stram DO; Ek WE; Onstad LE; MacGregor S; Gharahkhani P; Ye W; Lagergren J; Shaheen NJ; Murray LJ; Hardie LJ; Gammon MD; Chow WH; Risch HA; Corley DA; Levine DM; Whiteman DC; Bernstein L; Bird NC; Vaughan TL; Wu AH
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1801-3. PubMed ID: 26364162
[TBL] [Abstract][Full Text] [Related]
47. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.
Kaz AM; Grady WM; Stachler MD; Bass AJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):473-89. PubMed ID: 26021206
[TBL] [Abstract][Full Text] [Related]
48. Genomic regions associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture study.
Sun X; Chandar AK; Canto MI; Thota PN; Brock M; Shaheen NJ; Beer DG; Wang JS; Falk GW; Iyer PG; Abrams JA; Venkat-Ramani M; Veigl M; Miron A; Willis J; Patil DT; Nalbantoglu I; Guda K; Markowitz SD; Zhu X; Elston R; Chak A
PLoS One; 2017; 12(10):e0184962. PubMed ID: 29073141
[TBL] [Abstract][Full Text] [Related]
49. Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression.
Hamilton JP; Sato F; Jin Z; Greenwald BD; Ito T; Mori Y; Paun BC; Kan T; Cheng Y; Wang S; Yang J; Abraham JM; Meltzer SJ
Clin Cancer Res; 2006 Nov; 12(22):6637-42. PubMed ID: 17121882
[TBL] [Abstract][Full Text] [Related]
50. The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett's Esophagus.
Eluri S; Brugge WR; Daglilar ES; Jackson SA; Styn MA; Callenberg KM; Welch DC; Barr TM; Duits LC; Bergman JJ; Shaheen NJ
Am J Gastroenterol; 2015 Jun; 110(6):828-34. PubMed ID: 26010308
[TBL] [Abstract][Full Text] [Related]
51. In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett's sequence.
Götzel K; Chemnitzer O; Maurer L; Dietrich A; Eichfeld U; Lyros O; Moulla Y; Niebisch S; Mehdorn M; Jansen-Winkeln B; Vieth M; Hoffmeister A; Gockel I; Thieme R
BMC Gastroenterol; 2019 Mar; 19(1):38. PubMed ID: 30841855
[TBL] [Abstract][Full Text] [Related]
52. LINE-1 expression and retrotransposition in Barrett's esophagus and esophageal carcinoma.
Doucet-O'Hare TT; Rodić N; Sharma R; Darbari I; Abril G; Choi JA; Young Ahn J; Cheng Y; Anders RA; Burns KH; Meltzer SJ; Kazazian HH
Proc Natl Acad Sci U S A; 2015 Sep; 112(35):E4894-900. PubMed ID: 26283398
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.
Del Portillo A; Lagana SM; Yao Y; Uehara T; Jhala N; Ganguly T; Nagy P; Gutierrez J; Luna A; Abrams J; Liu Y; Brand R; Sepulveda JL; Falk GW; Sepulveda AR
J Mol Diagn; 2015 Jul; 17(4):412-9. PubMed ID: 26068095
[TBL] [Abstract][Full Text] [Related]
54. Applying big GWAS data to clarify the role of obesity in Barrett's esophagus and esophageal adenocarcinoma.
Abrams JA; Chak A
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25269700
[No Abstract] [Full Text] [Related]
55. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic correlation between the expression of the DNA repair enzyme N-methylpurine DNA glycosylase and esophageal adenocarcinoma onset: a retrospective pilot study.
Zaïr ZM; Johnson GE; Griffiths AP; Jenkins GJ
Dis Esophagus; 2013 Aug; 26(6):644-50. PubMed ID: 23137018
[TBL] [Abstract][Full Text] [Related]
57. A risk variant for Barrett's esophagus and esophageal adenocarcinoma at chr8p23.1 affects enhancer activity and implicates multiple gene targets.
Ali MW; Chen J; Yan L; Wang X; Dai JY; Vaughan TL; Casey G; Buas MF
Hum Mol Genet; 2022 Nov; 31(23):3975-3986. PubMed ID: 35766871
[TBL] [Abstract][Full Text] [Related]
58. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
59. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.
Smith E; De Young NJ; Pavey SJ; Hayward NK; Nancarrow DJ; Whiteman DC; Smithers BM; Ruszkiewicz AR; Clouston AD; Gotley DC; Devitt PG; Jamieson GG; Drew PA
Mol Cancer; 2008 Oct; 7():75. PubMed ID: 18831746
[TBL] [Abstract][Full Text] [Related]
60. Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma.
Beilstein M; Silberg D
Gastroenterol Clin North Am; 2002 Jun; 31(2):461-79, ix. PubMed ID: 12134613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
